CDX bispecific antibody (HemoGenyx)

N/A

Report date: 2026/03/19 16:53:40

Base Information

Drug NameCDX bispecific antibody (HemoGenyx)
Drug Alias Nameanti-CD3/anti-FLT3 bispecific T-cell engager (HemoGenyx)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionT cell surface glycoprotein CD3 modulatorsTyrosine-protein kinase receptor FLT3 modulators
TargetsT cell surface glycoprotein CD3Tyrosine-protein kinase receptor FLT3
Therapy Area/IndicationsLeukemia, Myeloid, AcutePrecursor Cell Lymphoblastic Leukemia-LymphomaLeukemia +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesEli Lilly And Company
China Registration ClassN/A

Develop Information

Active CompaniesHemogenyx Pharmaceuticals PLC
Inactive CompaniesEli Lilly And Company
Active IndicationsLeukemia, Myeloid, AcutePrecursor Cell Lymphoblastic Leukemia-LymphomaHematopoietic stem cell transplantation (HSCT)
Inactive IndicationsLeukemia

Other Information

ATC CodeN/A
Related LinksN/A